医学
前列腺癌
癌症
激素疗法
肿瘤科
疾病
放射治疗
雄激素剥夺疗法
内科学
局限性疾病
前列腺
作者
Mark S. Litwin,Hung‐Jui Tan
出处
期刊:JAMA
[American Medical Association]
日期:2017-06-27
卷期号:317 (24): 2532-2532
被引量:1359
标识
DOI:10.1001/jama.2017.7248
摘要
Advances in the diagnosis and treatment of prostate cancer have improved the ability to stratify patients by risk and allowed clinicians to recommend therapy based on cancer prognosis and patient preference. Initial treatment with chemotherapy can improve survival compared with androgen deprivation therapy. Abiraterone, enzalutamide, and other agents can improve outcomes in men with metastatic prostate cancer resistant to traditional hormonal therapy.
科研通智能强力驱动
Strongly Powered by AbleSci AI